GOLDEN, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced expansion of its core manufacturing capacity to meet growing demand for its “Tools for Stem Cell and Drug Development™” product line that was introduced earlier in the year. Demand for certain products exceeds present manufacturing capacity and requires significant scale-up to meet this demand. Vitro also recently completed its current fiscal year and will be reporting a substantial increase in sales due to early sales of its stem cell infrastructure product line, which occurred during the latter half of the year. The Company projects achievement of profitability during fiscal year 2010.
